(Q48599660)

English

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

scientific article published on 23 August 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. (English)

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

phase III clinical trial

0 references

multiple myeloma

1 reference

based on heuristic

inferred from title

Athanasios Dimopoulos

1

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

6

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

object named as

Roman Hajek

10

0 references

9

object named as

Thierry Facon

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

Ruben Niesvizky

3

object named as

Ruben Niesvizky

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

Hartmut Goldschmidt

2

object named as

Hartmut Goldschmidt

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

Philippe Moreau

17

object named as

Philippe Moreau

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

8

object named as

Heinz Ludwig

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

Robert Z Orlowski

7

object named as

Robert Z Orlowski

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

11

object named as

Katja Weisel

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

12

object named as

Vania Hungria

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

5

object named as

Wee-Joo Chng

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

13

object named as

Leonard Minuk

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

Anita Zahlten-Kumeli

15

object named as

Anita Zahlten-Kumeli

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

author name string

Douglas Joshua

4

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

Shibao Feng

14

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

Amy S Kimball

16

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

publication date

23 August 2017

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

Lancet Oncology Commission

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

18

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

10

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

1327-1337

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930578-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment options for relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930578-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930578-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930578-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930578-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Endpoints for assessing drug activity in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930578-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930578-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Surrogate End Points and Their Validation in Oncology Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930578-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930578-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930578-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930578-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930578-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930578-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930578-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930578-8

7 January 2021

based on heuristic

inferred from DOI database lookup

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930578-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A group sequential Holm procedure with multiple primary endpoints

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930578-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930578-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930578-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930578-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930578-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930578-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(17)30578-8

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

1 reference

Europe PubMed Central

13 February 2018

http://europepmc.org/abstract/MED/28843768

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48599660&oldid=1858029990"